| P50 | author | Timothy Synold | Q78536675 |
| P2093 | author name string | Jun Wu | |
| | Bingsen Zhou | |
| | Shuya Hu | |
| | Yun Yen | |
| | Leila Su | |
| | Weidong Hu | |
| | Yate-Ching Yuan | |
| | M L Richard Yip | |
| | Shikha Gaur | |
| | D Lynne Smith | |
| | David Horne | |
| P2860 | cites work | Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells | Q47613247 |
| | Preserved catalytic activity in an engineered ribonucleotide reductase R2 protein with a nonphysiological radical transfer pathway. The importance of hydrogen bond connections between the participating residues | Q47724421 |
| | The first holocomplex structure of ribonucleotide reductase gives new insight into its mechanism of action | Q50081626 |
| | A fast flexible docking method using an incremental construction algorithm. | Q52298930 |
| | Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. | Q54061261 |
| | Ribonucleotide reductase inhibition by p-alkoxyphenols studied by molecular docking and molecular dynamics simulations. | Q54352162 |
| | A rapid assay for CDP reductase activity in mammalian cell extracts | Q71495206 |
| | Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea | Q72551680 |
| | A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma | Q80478185 |
| | Structural interconversions modulate activity of Escherichia coli ribonucleotide reductase | Q27676130 |
| | Structure of ribonucleotide reductase protein R1 | Q27730848 |
| | A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage | Q28138556 |
| | Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors | Q28187466 |
| | Structure, function, and mechanism of ribonucleotide reductases | Q30164061 |
| | Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate | Q33784748 |
| | Ribonucleotide reductases | Q34067559 |
| | p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest. | Q34592077 |
| | Structural basis on the dityrosyl-diiron radical cluster and the functional differences of human ribonucleotide reductase small subunits hp53R2 and hRRM2. | Q34632044 |
| | Clofarabine 5'-di and -triphosphates inhibit human ribonucleotide reductase by altering the quaternary structure of its large subunit | Q35049193 |
| | Radical initiation in the class I ribonucleotide reductase: long-range proton-coupled electron transfer? | Q35150156 |
| | Ribonucleotide reductase inhibitors and future drug design | Q36569850 |
| | The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments | Q36721355 |
| | Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents | Q37066981 |
| | A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium | Q37327229 |
| | Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor | Q38299722 |
| | Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study | Q39466509 |
| | Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer | Q40240925 |
| | Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line | Q40929262 |
| | Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy | Q41014828 |
| | The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation | Q41048019 |
| | Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential | Q41058506 |
| | Identification of the stable free radical tyrosine residue in ribonucleotide reductase. | Q42572329 |
| | SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes | Q44775677 |
| | A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer | Q44899958 |
| | Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay | Q45238116 |
| | Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. | Q46579981 |
| | pH Rate profiles of FnY356-R2s (n = 2, 3, 4) in Escherichia coli ribonucleotide reductase: evidence that Y356 is a redox-active amino acid along the radical propagation pathway | Q46920321 |
| | Site-specific replacement of Y356 with 3,4-dihydroxyphenylalanine in the beta2 subunit of E. coli ribonucleotide reductase | Q46955368 |
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell growth | Q189159 |
| | drug resistance | Q12147416 |
| P304 | page(s) | 6484-6493 | |
| P577 | publication date | 2013-09-26 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance | |
| P478 | volume | 73 | |